CN114028421A

CN114028421A - A method for treating eye diseases by using poloxamer

Info

Publication number: CN114028421A
Application number: CN202111293468.0A
Authority: CN
Inventors: 张国华
Original assignee: Individual
Current assignee: Individual
Priority date: 2021-11-03
Filing date: 2021-11-03
Publication date: 2022-02-11

Abstract

Disclosed is a method for treating ocular diseases, which comprises preparing a pharmaceutical agent by adding an adjuvant to poloxamer, and treating and restoring ocular diseases including conjunctivitis, keratitis, xerophthalmia, meibomian gland dysfunction, intraoculous tumors, sjogren's syndrome, ocular surface fibrosis, pterygium, etc. by local administration; uveitis: ciliary inflammation of retina, choroiditis, ophthalmia, subacute fundus macular atrophy, and Hodgkin's disease. The poloxamer can help the patients to recover as soon as possible when being used for treating eye diseases, and clinical tests show that the poloxamer has obvious effect and quick response, treats both principal and secondary aspects of diseases, does not have allergy or other reactions, and does not bring side effects; is not easy to generate drug resistance, and has great significance for treating eye diseases.

Description

A method for treating eye diseases by using poloxamer

Technical Field

The invention relates to the technical field of medicines, in particular to a method for treating eye diseases by using poloxamer.

Background

Poloxamers (poloxamers) are nonionic block copolymers of Ethylene Oxide (EO) and Propylene Oxide (PO). They are used as surfactants, emulsifiers, solubilizers and dispersants in pharmaceutical preparations. Various eye diseases such as myopia, amblyopia, dry eyes, eye acerbity, eye swelling, eye pain, eye acid, eye lacrimation, blurred vision and the like bring pain to patients. At present, the quantity of medicines for treating eye diseases is small, and poloxamers are not applied to treating the eye diseases in the prior art.

Disclosure of Invention

In view of the above, the present invention aims to provide a method for treating eye diseases using poloxamer, which solves the problems of the prior art.

A method for treating eye diseases with poloxamer, which comprises adding adjuvants to prepare poloxamer into medicine, and topically administering to treat eye diseases and restore normal state.

Further, the ocular diseases include conjunctivitis, keratitis, dry eye, meibomian gland dysfunction, tumors in the eye, sjogren's syndrome, ocular surface fibrosis, pterygium; uveitis: ciliary inflammation of retina, choroiditis, ophthalmia, subacute fundus macular atrophy, and Hodgkin's disease.

Further, the ocular diseases include upper eyelid and lacrimal disorders, blepharitis, hordeolum, meibomian gland cyst, eyelid inversion, eyelid eversion, allergic dermatitis, dacryocystitis, upper eyelid malignancy, lacrimal gland disorders.

Further, the ocular disease includes ocular lens disorders: the ectopic and abnormal shape of the eye lens, and the periocular degeneration caused by various glaucoma, fundus macular disease, ametropia, pseudomyopia heterophylly of oblique vision, various eye traumas, sexual eye diseases and full-bodied diseases.

Further, the medicament is one of a suspension, a spray formulation or an emulsion containing liposome or micelle and one of oral preparations, including tablets, sustained release tablets or liquid.

Further, the administration may be by injection, topical or oral administration, wherein topical is an ophthalmic formulation in the form of a topical ocular formulation or ocular implant, which is in the form of a semi-solid or solid sustained release implant, wherein the implant is injected into the eye of the subject.

Further, one of the external preparations is a solution, a suspension, a cream, an ointment, a gel-forming liquid, etc. and an oral preparation includes meibomian gland dysfunction, a tumor in the eye, sicca syndrome, ocular surface fibrosis, pterygium in any form of ocular administration.

By adopting the technical scheme, the method has the following beneficial effects:

the poloxamer can help the patients to recover as soon as possible when being used for treating eye diseases, and clinical tests show that the poloxamer has obvious effect and quick response, treats both principal and secondary aspects of diseases, does not have allergy or other reactions, and does not bring side effects; is not easy to generate drug resistance, and has great significance for treating eye diseases.

Detailed Description

The technical solution of the present invention is described in more detail and fully below.

Example 1: the present invention aims to provide a method for treating ocular diseases using poloxamers, which was further tested in order to verify the therapeutic effect.

100 eye disease patients are recruited, and the patients are graded according to the three grades of light, medium and serious diseases;

reagent: poloxamer purity 50%);

the poloxamer is added with auxiliary materials to prepare the externally applied eye drops which are dripped into eyes of patients, and the eye drops have no obvious acute toxic reaction, no irritation and no local and general anaphylactic reaction.

Example 2: 100 eye disease patients are recruited, and the patients are graded according to the three grades of light, medium and serious diseases;

reagent: poloxamer purity 70%);

Example 3: test materials: 100 eye disease patients are recruited, and the patients are graded according to the three grades of light, medium and serious diseases;

reagent: poloxamer purity 80%);

Patient disease grade	Example 1 (% treatment)	Example 2 (% treatment)	Example 3 treatment Rate%)
				Mild degree of	50	60	80
Of moderate degree	40	50	70
				Severe degree	30	40	50

According to the results, the following results are shown: the poloxamer has good therapeutic effect on eye diseases.

Having thus described the basic principles and principal features of the invention, it will be appreciated by those skilled in the art that the invention is not limited by the embodiments described above, which are given by way of illustration only, but that various changes and modifications may be made therein without departing from the spirit and scope of the invention as defined by the appended claims and their equivalents.

Claims

1. A method for treating eye diseases by using poloxamer, which is characterized in that the poloxamer is prepared into a medicament by adding auxiliary materials, and the medicament can treat eye diseases and restore normal state by local administration.

2. The method of claim 1, wherein the ocular disease comprises conjunctivitis, keratitis, xerophthalmia, meibomian gland dysfunction, intraoculous tumors, sjogren's syndrome, ocular surface fibrosis, pterygium; uveitis: ciliary inflammation of retina, choroiditis, ophthalmia, subacute fundus macular atrophy, and Hodgkin's disease.

3. A method of using poloxamers for the treatment of ocular diseases according to claim 1 wherein the ocular diseases include upper eyelid and lacrimal disorders, blepharitis, meibomitis, meibomian gland cyst, eyelid inversion, eyelid eversion, allergic dermatitis, dacryocystitis, upper eyelid malignancies, lacrimal disorders.

4. The method of claim 1, wherein the ocular disease comprises an ocular lens disorder: the ectopic and abnormal shape of the eye lens, and the periocular degeneration caused by various glaucoma, fundus macular disease, ametropia, pseudomyopia heterophylly of oblique vision, various eye traumas, sexual eye diseases and full-bodied diseases.

5. The method of claim 1, wherein the pharmaceutical agent is one of a liposome or micelle containing suspension, spray formulation or emulsion and one of an oral formulation comprising a tablet, a sustained release tablet or a liquid.

6. A method of using poloxamers for the treatment of ocular diseases according to claim 1 wherein the administration is by injection, topical or oral administration wherein the topical ophthalmic formulation is in the form of a topical ocular formulation or ocular implant, the ocular implant being in the form of a semi-solid or solid sustained release implant, wherein the implant is injected into the eye of the subject.

7. The method for treating ocular diseases using poloxamer as claimed in claim 1, wherein the external preparation is one of a solution, suspension, cream, ointment, gel-forming liquid, etc. and an oral preparation comprising meibomian gland dysfunction, intra-ocular tumor, sjogren's syndrome, ocular surface fibrosis, pterygium in any form of ocular administration.